ocugen stock price target

Ratings Network’s free daily newsletter. 4 Wall Street analysts have set twelve-month price targets for Ocugen in the last year. PriceTargets.com does not provide financial advice and does not issue recommendations or offers to buy stock or This Little-Known Lithium Explorer May About to Rocket. And there's something that every cannabis investor needs to see... Get New Ocugen Analyst Ratings Delivered To Your Inbox. The following Wall Street analysts have issued research reports on Ocugen in the last twelve months: Cantor Fitzgerald, Chardan Capital, HC Wainwright, Roth Capital, and Zacks Investment Research. The average price target is $8.38, with a high forecast of $11.00 and a low forecast of $4.50. The stock has a consensus analyst rating of "Buy." Their average twelve-month price target is $8.38, predicting that the stock has a possible downside of 2.73%. Ocugen aims to launch the two-dose vaccine for the U.S. market in the second quarter of 2021. Why Ocugen Stock Is Tanking Today Shares of Ocugen (NASDAQ: OCGN) were tanking by 12.7% as of 11:16 a.m. EDT on Friday after falling as much as 20.6% earlier in the day. Presently, Ocugen Inc. shares are logging -53.38% during the 52-week period from high price, and 5047.06% higher than the lowest price point for the same timeframe. © American Consumer News, LLC dba MarketBeat® 2010-2021. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. What is OCGN's Price Target? Want to see which stocks are moving? This suggests that the stock has a possible downside of 2.3%. The target price of €2.00 compared with the current price of €5.69 for the stock indicates a negative potential of -64.875%. 0.17. -3.17 / -20.22%. Ad - Prosper Trading Academy 16 Scott B … Start Your Risk-Free Trial Subscription Here, The Container Store Has What Every Growth Stocks Needs, Don’t Rush To Buy Walmart, Extra Low Prices Are On The Way, Legal Issues Behind It, IBIO Stock May Be a Long Play For Risk-Tolerant Investors, Steel Producers Extend Their One-Year Gains On Strong Demand, Lumentum Stock Providing Opportunistic Pullbacks, 3 Stocks to Play the Shopping Mall Revival, Snowflake (NYSE: SNOW) Starts To Look Hot, 7 Cyclical Stocks That Can Help You Play Defense, 7 Stocks That Could Benefit From a Capital Gains Tax Hike, 7 Forever Stocks That Are Never Bad to Buy, 7 Stocks That Still Have Upside For Investors to Buy, 7 Precious Metals Stocks That Will Keep Your Portfolio On Trend, 7 Bellwether Stocks Signaling a Return to Normal, 7 Electric Vehicle (EV) Stocks That Are Ready to Rebound, 7 Sports Betting Stocks That Will Shine Beyond March Madness, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, Receive Analysts' Upgrades and Downgrades Daily. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. This price target is based on 4 analysts offering 12 month price targets for Ocugen in the last 3 months. Emergency Use Authorization (EUA) for COVID-19 vaccine Covaxin. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. OCUGEN INC OCGN STOCK CHART ANALYSIS | NEW PRICE TARGET BY ANALYSIS RATINGS OF $8 ALMOST REACHED ! Get short term trading ideas from the MarketBeat Idea Engine. The average price target is $8.38, with a high forecast of $11.00 and a low forecast of $4.50. Shares of Ocugen - a gene therapy firm that aims to cure blindness and is also working on a new coronavirus vaccine - pulled back by 3.9% to finish Wednesday at US$11.21. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Overall, the consensus on the Street is that OCGN is a Strong Buy, based on 3 Buys and 1 Hold. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). See what's happening in the market right now with MarketBeat's real-time news feed. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. The average price target represents a -4.29% upside from the last price of $8.75. - YouTube. This may be the next lithium giant to feed surging global battery demand for EVs! Analysts stock forecasts for Ocugen stock Firstly, across the board of Wallstreet analysts the general consensus is a Buy. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Ocugen currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The dark blue line represents the company's actual price. This price target is based on 4 analysts offering 12 month price targets for Ocugen in the last 3 months. MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. A new-to-market sector is flying below the radar…and one stock has a major advantage that can help it capitalize on the sector’s forecasted 104% CAGR. OCGN Stock News Comes as JNJ Vaccine Remains on Pause. See Full OCGN Report . They are not Tesla investors. Ocugen (OCGN) Stock Price Predictions | Bharat Biotech Crisis & More Pressure On Biden! You can opt out at any time. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. 4 Wall Street analysts have issued ratings and price targets for Ocugen in the last 12 months. View which stocks are hot on social media with MarketBeat's trending stocks report. Identify stocks that meet your criteria using seven unique stock screeners. According to 4 Wall Street analysts that have issued a 1 year OCGN price target, the average OCGN price target is $7.38 , with the highest OCGN stock price forecast at $13.00 and the lowest OCGN stock price forecast at $1.00 . To see all exchange delays and terms of use please see disclaimer. This is most likely a result of the stock… © American Consumer News, LLC dba PriceTargets.com ® 2010-2021. The stock price of Ocugen Inc (NASDAQ: OCGN) has received a price target increase by Chardan Capital from $0.70 to $13. Their average twelve-month price target is $8.38, predicting that the stock has a possible downside of 3.40%. HC Wainwright raised shares of Ocugen from a neutral rating to a buy rating and set a $4.50 price target for the company in a research report on Thursday, February 4th. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. The high price target for OCGN is $11.00 and the low price target for OCGN is $4.50. Ocugen (NASDAQ:OCGN) had its target price raised by Cantor Fitzgerald from $1.00 to $4.00 in a report released on Wednesday morning, The Fly reports. The lighter blue line represents the stock's consensus price target. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). These factors prompted Cantor Fitzgerald analyst Kristen Kluska to raise her price target on Ocugen stock to $4, up from $1. Learn about financial terms, types of investments, trading strategies and more. The shares of Ocugen Inc (NASDAQ: OCGN) have received a $10 price target by Roth Capital. And Roth Capital analyst Zegbeh Jallah assigned Ocugen a “Buy” rating. Move your mouse over past months for details. Three of the analysts recommend the stock as a buy, with one rating it a hold. Negative data or inability to secure an EUA (Emergency Use Authorisation) is a key downside risk to the stock from current levels.” Chadran’s Keay Nakae raised his target price to $13 from $0.70, although he cut his rating to ‘neutral’ from ‘overweight’. Despite the day-on-day decline, that is still the stock’s strongest close since early February 2021. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy.". You can opt out at any time. Investor Alert: The 2021 Cannabis "Legalization Boom". Ocugen (NASDAQ:OCGN) Price Target Increased to $8.00 by Analysts at Roth Capital. Learn more about MarketBeat. View the latest ratings for OCGN. The company has an average price target of $2.55. Ocugen (NASDAQ:OCGN) had its price objective hoisted by Roth Capital from $1.00 to $8.00 in a report published on Wednesday, The Fly reports. The analyst also kept an overweight rating on the stock. The high price target for OCGN is $11.00 and the low price target for OCGN is $4.50. View our full suite of financial calendars and market data tables, all for free. All rights reserved. Ocugen stock is selling for 9.19 as of the 8th of May 2021. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Analysts might take a new look at the stock … Equity ratings for Ocugen Inc are calculated daily … Their forecasts range from $4.50 to $11.00. View the latest price targets for OCGN. To see all exchange delays and terms of use please see disclaimer. Ocugen, Inc (OCGN) Stock! Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Over the past week, OCGN shares had nearly … The average 12-month price target from four analysts that have issued an Ocugen share price forecast is $4.80 per share, with a high estimate of $10 per share and a low of $0.70 per share. Ever since that announcement, the stock has been on a tear, leaving Chardan analyst Keay Nakae's previous $0.70-per-share price target in the dust.. Export data to Excel for your own analysis. Ocugen Inc has a Long-Term Technical rank of 100. Ocugen Inc (NASDAQ:OCGN) Ocugen Inc. 12.50. Receive a free world-class investing education from MarketBeat. Fundamental company data provided by Zacks Investment Research. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. A "buy" rating indicates that analysts believe OCGN will outperform the market and that investors should add to their positions of Ocugen. changes. This is a -4.07% down since the beginning of the trading day. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). On the other hand, Ocugen's target price is what analysts think the stock is worth or could sell for in the future. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. OCGN has an Overall Score of 67. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. The stock's open price was 9.58.Ocugen has 53 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Cantor Fitzgerald does not see either upside or downside right now … For the coming years our community has positive and negative things to say abot the Ocugen Inc. stock. The stock’s price range for the 52-week period … Press Release reported on 05/13/21 that Thinking about buying stock in Sundial Growers, P Several other equities analysts have also issued reports on OCGN. 326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257 The average 12 month price target from analysts is at $12.50 a share according to WSJ data. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Delayed Data. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. But investors in this company could end up really happy if the Lithium Megatrend continues.document.write(''); View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. If playback doesn't begin shortly, try restarting your device. Posted by Brenda Bartman on Feb 7th, 2021. HC Wainwright has the lowest price target set, forecasting a price of $4.50 for Ocugen in the next year. Get daily stock ideas top-performing Wall Street analysts. Today’s Change. 4 Wall Street analysts have issued 1-year target prices for Ocugen's stock. Ocugen's current and average target prices are 8.23 and 0.90, respectively. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. PriceTargets.com keeps track of all major brokerages’ stock ratings and recommendations, including Goldman Sachs, JPMorgan Chase, Wells Fargo, Bank of America/Merrill Lynch, Citigroup, Morgan Stanley and many more. HUGE Potential, Price Target! Ocugen stock has a median target price of $1, which is a premium of 24 percent over its closing prices on Dec. 22. Full legalization may change the investing world forever. Our Accessibility Statement | Terms of Service | Do Not Sell My Information. The chart below shows how a company's share price and consensus price target have changed over time. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Ocugen is still up 280% year-to-date and 2,137% (21 times) in the past year. On average, they anticipate Ocugen's share price to reach $8.38 in the next year. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. Ocugen Inc. analyst ratings, historical stock prices, earnings estimates & actuals. As of May 04. The current consensus among 4 contributing investment analysts is to buy stock in Ocugen. The average price target represents a -3.40% upside from the last price of $8.67. HC Wainwright reiterated a hold rating on shares of Ocugen in a research note on Monday, … Roth Capital raised their price target on shares of Ocugen from $9.00 to $10.00 and gave the stock a buy rating in a research note on Thursday, March 4th. This rating has held steady since October 2020, when it changed from a Hold consensus rating. Looking for new stock ideas? Ocugen's physical mailing address is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Cantor Fitzgerald has the highest price target set, predicting OCGN will reach $11.00 in the next twelve months. Sign-up to receive the latest news and ratings for OCGN and its competitors with Analyst 326 E 8th St #105, Sioux Falls, SD 57103. The company is headquartered in Malvern, Pennsylvania. Ocugen Inc. (NASDAQ:OCGN) went up by 6.32% from its latest closing price compared to the recent 1-year high of $18.77. America! The Newest Lithium Player Fueling the Green Revolution. The company’s stock price has collected -4.74% of loss in the last five trading sessions. 4 Wall Street analysts have issued ratings and price targets for Ocugen in the last 12 months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. The company's listed phone number is 484-328-4701 and its investor relations email address is [email protected] The official website for Ocugen is ocugen.com. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 0% of the market … OCGN: Get the latest Ocugen stock price and detailed information including OCGN news, historical charts and realtime prices. They currently have a buy rating on the stock. MUST WATCH! Please log in to your account or sign up in order to add this asset to your watchlist. Time To Buy!! Their average twelve-month price target is $8.38, suggesting a possible downside of 9.9%. OCUGEN : Chardan Adjusts Price Target on Ocugen to $8 From $13, Maintains Neutral Rating However, the Strong Buy consensus rating is backed with a $0.9 price target, which implies downside of 68% from current levels. Prior to their COVID-19 vaccine developments, the companies average price target was around $0.98 a share. View the latest analyst ratings for OCGN. This small cap explorer may be sitting on one of the biggest lithium finds in No. Instead, the bigger issue was probably that the company still hasn't made tangible progress toward securing U.S. In recent trading, shares of Ocugen Inc (Symbol: OCGN) have crossed above the average analyst 12-month target price of $12.50, changing hands for $12.67/share. OCUGEN : Chardan Adjusts Price Target on Ocugen to $8 From $13, Maintains Neutral Rating Ocugen stock price hits two-month high. Find out what this means to you and get the rest of the rankings on OCGN! OCGN updated stock price target summary. PriceTargets.com provides comprehensive coverage of stock ratings, including equities research analysts’ upgrades, downgrades, new coverage and price target We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. The average analyst price target of $12.50 implies that the stock has an … sell any security. All rights reserved. The current price of Ocugen is the price at which Ocugen Inc is currently trading. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. The average target price for the stock is $4.8, which implies a downside potential of nearly 30 percent. They currently have an overweight rating on the stock. Fundamental company data provided by Zacks Investment Research. Other companies that are similar to Ocugen include Fate Therapeutics, Denali Therapeutics, Halozyme Therapeutics, Vir Biotechnology, Adaptive Biotechnologies, China Biologic Products, Twist Bioscience, Beam Therapeutics, Kodiak Sciences, Allogene Therapeutics, Iovance Biotherapeutics, Ablynx, SpringWorks Therapeutics, Bavarian Nordic A/S and Relay Therapeutics. However, Chardan Capital downgraded the stock to “Neutral” from “Buy” based on the recent stock price surge.

Brad Park Norris Trophy, Highest Scoring Nba Game Regulation, To Place Or Add Something In Something Else In Computer, How To Watch Fox Turkey Online, Ohio Outlaws Location, Johnson University Jobs,

Submitted in: Sin categoría |